Access Is Not Approval

Opening Sermon · Fiction

FICTIONAL CONTINUITY: Epistide found a new sign outside the chapel: “Conditional Access.” Someone had already ordered “Miracle Approved” banners. Doctide confiscated the receipt.

Regulatory Gospel · Approval and policy

Material change since the previous edition: HHS released its peptide-compounding enforcement policy on October 28. The October 30 Federal Register notice describes the policy as draft, interim and nonbinding while formal rulemaking proceeds. This replaces the previous edition’s “policy under review” situation. It is not FDA drug approval. Federal Register notice, October 30.

The posted policy covers BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500, subject to specified conditions. These include precise ingredient identities, quality documentation, manufacturing safeguards, patient-specific prescriptions, labeling and safety reporting.

One consequential boundary: products must contain a single listed active ingredient. The policy therefore does not extend to a combined BPC-157/TB-500 “Wolverine” formulation. Retatrutide is not among the six listed substances.

Approved human use: The policy grants none of these substances an approved indication. Access conditions and evidence of clinical benefit remain separate questions. HHS policy and appendices.

Scientific Revelations · Controlled human evidence

Sponsor-reported phase 3 results—not yet peer reviewed: Lilly’s October 28 announcement describes TRANSCEND-T2D-2, a randomized, open-label comparison involving 1,298 adults with type 2 diabetes.

At 80 weeks, the two retatrutide groups had estimated average weight reductions of 19.5% and 20.9%, versus 9.4% with Ozempic. A1C fell 2.2 percentage points in both retatrutide groups versus 1.8 points with Ozempic.

These are efficacy-estimand results: estimates assuming continued treatment without additional glucose-lowering medication. They are not guaranteed outcomes for everyone starting treatment. The comparator was the highest approved Ozempic regimen for diabetes—not every semaglutide formulation or obesity regimen.

Gastrointestinal events were common. Adverse-event discontinuations were 4.8% and 7.9% with retatrutide versus 2.7% with Ozempic; altered skin sensation was also more frequent.

Retatrutide remains investigational. Full publication and additional long-term evidence are still needed. Lilly disclosure, October 28.

Human Record · Observation and practice

Peer-reviewed observational evidence: An October 27 JAMA Network Open study examined prescribing using 2017–2022 Medicare claims for 177,284 people with type 2 diabetes, treated by 1,061 endocrinologists.

Following guideline updates, appropriate GLP-1 prescription fills increased modestly. Higher physician knowledge-assessment scores were associated with changes in SGLT2-inhibitor prescribing, but the corresponding GLP-1 association was not statistically significant.

This studies implementation of evidence in practice. It does not prove that an examination caused better prescribing, measure contemporary 2026 access, or establish a new treatment benefit. Original study, October 27.

From the Laboratory · Evidence boundaries

Animal research: No additional animal finding was verified for inclusion in this edition.

In-vitro mechanisms: No additional laboratory finding was verified for inclusion.

Unsupported claims: Neither the new access policy nor commercial enthusiasm establishes the advertised recovery or longevity benefits of the six peptides. Regulatory discretion does not turn a mechanistic hypothesis into a demonstrated patient outcome.

Market Tithe · Profitide, fictional Keeper of the Market Tithe

FICTIONAL COMMENT — PROFITIDE: “The headline has already spent next year’s revenue. Accounting would like a word.”

Confirmed company disclosure — Lilly, NYSE: LLY: On October 29, Lilly reported quarterly revenue of $24.4 billion, up 39% year over year. Volume increased 53%, partly offset by lower realized prices. Full-year revenue guidance rose to $91–92 billion. These are company-wide results and forecasts, not retatrutide sales. Lilly earnings release, October 29.

Confirmed manufacturing-sector transaction update — PolyPeptide, SIX: PPGN: Shareholders approved proposed governance changes on October 26, including directors whose appointments become effective upon settlement of Samsung Peptide’s tender offer. This advances transaction preparations; it does not establish that the acquisition has closed or new manufacturing capacity is operating. PolyPeptide disclosure, October 26.

Dated market movement: GuruFocus’s TradingView report recorded LLY at $1,297.37, up 1.21%, at 11:24 a.m. Eastern on October 28. This is an intraday observation—not a closing price—and predates October 29 earnings. It cannot isolate the trial announcement’s effect. Market report, October 28.

Editorial inference: Clinical competition and manufacturing consolidation are progressing together, but neither guarantees future revenue or medical benefit. No additional material peptide-licensing announcement was verified for inclusion. No investment recommendation is offered.

Movements in the Canon / Those Awaiting Canonization

No canon or character change is proposed. Record the policy development separately from clinical evidence; retain retatrutide’s investigational status.

Further Reading · Deeper lecture

Three Different Doors: Access, Evidence and Approval

1. What enforcement discretion changes—and what it leaves unresolved.

2. Why single-ingredient products matter for interpreting safety.

3. How randomized, open-label and sponsor-reported evidence differ.

4. Why statistical estimands affect headline results.

5. How financial disclosures differ from commercial predictions.

Sacred Footnotes · Interests and limitations

Lilly sponsors the retatrutide program and has a financial interest in its success. PolyPeptide reports on its own transaction. In the prescribing study, two authors were ABIM employees and another received ABIM fees; those relationships matter when interpreting findings involving ABIM assessments.

Editorial preparation: Church of Peptides. Independent clinical review: none completed. Educational reporting only; no dosing, sourcing, medical or investment advice.

Publication note: October 30 edition, first published November 5. Research was prepared October 29; the October 30 Federal Register publication is incorporated above. Historical results and market timestamps retain their original dates.